



Nanotechnology in Modern Drug Delivery and Medical Treatment: Emerging Applications, Challenges and Future Perspectives

Mira Kovalenko

Institute of Digital Systems, Dnipro Valley University, Ukraine

Submission 02.04.2026 Acceptance: 02.06.2026 Publication: 31.08.2026

Abstract

Nanotechnology has emerged as an important interdisciplinary field in modern medicine, particularly in drug delivery, diagnosis, cancer treatment, gene therapy, vaccine development, regenerative medicine, and personalized healthcare. Conventional drug-delivery systems frequently encounter limitations such as poor aqueous solubility, rapid degradation, short circulation time, nonspecific distribution, low bioavailability, and systemic toxicity. Nanotechnology provides strategies for addressing several of these limitations by engineering materials and carriers at the nanoscale. Liposomes, polymeric nanoparticles, lipid nanoparticles, dendrimers, micelles, nanogels, inorganic nanoparticles, and hybrid nanocarriers can be designed to transport therapeutic molecules and release them in a controlled manner. Nanocarriers may improve drug solubility, prolong circulation, facilitate cellular uptake, and enable tissue-specific or stimulus-responsive delivery. These characteristics have generated considerable interest in cancer therapy, infectious diseases, neurological disorders, cardiovascular diseases, inflammatory conditions, and nucleic-acid therapeutics. Recent research has also expanded the role of nanotechnology toward RNA delivery, immunotherapy, theranostics, biomimetic nanoparticles, and precision medicine. Nevertheless, substantial challenges remain, including nanoparticle toxicity, biological interactions, manufacturing complexity, reproducibility, pharmacokinetic uncertainty, regulatory requirements, and difficulties in translating promising laboratory findings into routine clinical practice. Recent reviews emphasize that although nanomedicine has demonstrated considerable therapeutic potential, clinical translation requires robust biological validation, scalable manufacturing, standardized characterization, and interdisciplinary collaboration. This paper examines the principles of nanotechnology-based drug delivery, major nanocarrier systems, mechanisms of targeted delivery, applications in modern medical treatment, emerging therapeutic strategies, challenges, ethical and safety considerations, and future directions.

Keywords: Nanotechnology, Nanomedicine, Drug Delivery, Nanoparticles, Targeted Therapy, Liposomes, Lipid Nanoparticles, Cancer Therapy, Gene Delivery, Precision Medicine

1. Introduction

The development of effective drug-delivery systems is one of the central objectives of pharmaceutical and medical research. Although numerous therapeutic compounds have



demonstrated strong biological activity, their clinical usefulness can be limited by poor solubility, instability, rapid metabolism, inadequate absorption, nonspecific distribution, and toxicity. Conventional administration frequently exposes both diseased and healthy tissues to therapeutic compounds, potentially reducing the therapeutic index of treatment. These limitations have encouraged researchers to investigate advanced delivery platforms capable of transporting medicines more efficiently and selectively.

Nanotechnology has emerged as one of the most promising approaches in this field. Nanomedicine applies nanoscale materials and engineering principles to biological and medical problems. Nanoparticles can be designed with controlled size, morphology, surface chemistry, charge, composition, and functionalization. These properties can influence circulation, tissue distribution, cellular uptake, drug release, and biological interactions. Current research includes lipid-based nanoparticles, polymeric nanoparticles, micelles, dendrimers, hydrogels, inorganic nanoparticles, extracellular-vesicle-inspired systems, and hybrid nanostructures.

The importance of nanotechnology in medicine extends beyond conventional drug delivery. Nanomaterials are being investigated for diagnostic imaging, biosensing, tissue engineering, gene delivery, cancer immunotherapy, antimicrobial treatment, regenerative medicine, and combined diagnostic-therapeutic applications. Recent research has particularly emphasized the delivery of delicate biological molecules, including RNA and other nucleic acids, which require specialized protection and intracellular delivery.

The increasing development of nanomedicine does not mean that every nanoparticle-based system will automatically provide clinical benefits. Nanoparticles interact with proteins, immune cells, biological membranes, organs, and extracellular environments in complex ways. Their physicochemical characteristics can substantially influence their biological behaviour. Consequently, understanding nano-bio interactions, toxicity, pharmacokinetics, manufacturing, and long-term safety is as important as demonstrating therapeutic efficacy.

2. Fundamentals of Nanotechnology-Based Drug Delivery

Nanotechnology-based drug delivery involves the use of nanoscale structures to transport pharmaceutical or biological agents to particular locations in the body. The nanoscale provides a high surface-area-to-volume ratio and permits considerable control over surface properties. Researchers can attach therapeutic molecules, targeting ligands, imaging agents, or other functional components to nanoparticles.

One major objective is to improve the physicochemical properties of drugs. Poorly water-soluble compounds may have limited absorption and bioavailability. Encapsulation within suitable nanocarriers can increase apparent solubility and protect the drug from premature degradation. Nanocarriers can also provide controlled or sustained release, potentially reducing fluctuations in drug concentration and decreasing dosing frequency.

Another important objective is improving biodistribution. A conventional drug administered systemically may circulate throughout the body, reaching both target and non-target tissues.



Nanocarriers can potentially alter this distribution through their size, surface characteristics, and targeting mechanisms. The objective is not simply to transport more drug, but to increase the amount reaching the therapeutically relevant site while reducing unnecessary exposure elsewhere.

3. Major Nanocarriers Used in Medicine

3.1 Liposomes

Liposomes are spherical vesicles composed primarily of lipid bilayers. They can encapsulate hydrophilic compounds in an aqueous internal compartment while incorporating hydrophobic compounds within the lipid membrane. Their relatively flexible composition and established pharmaceutical development history have made them one of the most extensively investigated nanocarriers.

Liposomes can modify drug pharmacokinetics and distribution. Surface modification can further alter circulation time and interaction with biological systems. Their applications include anticancer drugs, antifungal medicines, vaccines, and other therapeutic agents.

3.2 Lipid Nanoparticles

Lipid nanoparticles have become particularly important for nucleic-acid delivery. Their significance increased substantially through the development of mRNA-based therapeutic and vaccine technologies. Lipid formulations can protect fragile RNA molecules from degradation and facilitate cellular uptake and intracellular release.

The successful application of lipid nanoparticles to nucleic-acid delivery demonstrated that nanotechnology can overcome important biological barriers that previously limited the clinical use of certain molecular therapies. Research is now exploring lipid nanoparticles for broader applications involving RNA therapeutics, gene-editing systems, and other biological medicines.

3.3 Polymeric Nanoparticles

Polymeric nanoparticles can be prepared from biodegradable or biocompatible polymers and engineered for controlled drug release. Their characteristics can be modified according to the therapeutic objective. Polymeric systems may protect encapsulated molecules, prolong drug release, and facilitate targeted delivery.

Recent reviews continue to identify polymeric nanoparticles as an important component of modern drug-delivery research, especially for cancer treatment and biological therapeutics.

3.4 Micelles and Nanogels

Micelles are nanoscale structures formed by amphiphilic molecules and are particularly useful for improving the apparent solubility of hydrophobic drugs. Nanogels are nanoscale, cross-linked polymeric networks capable of incorporating therapeutic molecules and responding to environmental conditions.

Both systems have potential for controlled delivery. Stimulus-responsive nanogels may release their payload when exposed to specific pH, temperature, enzymes, or other biological signals.

3.5 Dendrimers



Dendrimers are highly branched, regularly structured macromolecules with controllable surface chemistry. Their multiple functional groups provide opportunities for attaching therapeutic molecules, targeting ligands, or imaging components. Their structural uniformity makes them scientifically attractive, although toxicity, biodegradability, manufacturing, and clinical translation remain important considerations.

3.6 Inorganic Nanoparticles

Inorganic nanoparticles include materials such as gold, iron oxide, silica, and other engineered nanomaterials. Their optical, magnetic, catalytic, or structural characteristics can support applications extending beyond simple drug transport.

For example, iron-oxide nanoparticles may have both therapeutic and imaging applications, while gold nanoparticles have been investigated for photothermal treatment and targeted delivery. However, recent research emphasizes that the therapeutic potential of metal nanoparticles must be evaluated alongside concerns about toxicity, accumulation, and biological safety.

4. Targeted Drug Delivery

Targeted drug delivery is one of the most important goals of nanomedicine. It seeks to improve the concentration of therapeutic agents at disease sites while limiting exposure to healthy tissues.

Passive targeting relies on physiological characteristics of diseased tissues. In oncology, the enhanced permeability and retention phenomenon has historically provided an important rationale for nanoparticle accumulation in some solid tumours. However, tumour biology is heterogeneous, and nanoparticle distribution is not uniform across all tumours or even throughout an individual tumour.

Active targeting involves modifying nanoparticle surfaces with ligands that interact with receptors or molecules expressed by particular cells. Antibodies, peptides, proteins, and other recognition molecules can potentially improve cellular uptake. However, targeting a receptor does not guarantee successful delivery because nanoparticles must still overcome biological barriers, penetrate tissue, enter cells, escape intracellular compartments when necessary, and release their cargo.

Consequently, modern research increasingly investigates multistage or hierarchical targeting. Nanocarriers may be designed to change their size, surface charge, or ligand exposure in response to particular biological conditions. Such approaches attempt to overcome the conflicting requirements of circulation, tissue penetration, cellular uptake, and intracellular delivery.

5. Stimuli-Responsive Nanomedicine

Stimuli-responsive nanoparticles represent an important development in intelligent drug delivery. Instead of releasing their cargo continuously, these systems are designed to respond to specific internal or external stimuli.



Internal stimuli can include differences in pH, redox conditions, enzyme activity, or metabolite concentrations. Tumour tissues, for example, can possess microenvironmental characteristics that differ from normal tissues. Researchers can exploit such differences to design systems capable of releasing therapeutic compounds under selected conditions.

External stimuli may include light, magnetic fields, ultrasound, or temperature. Externally activated systems can theoretically provide additional control over treatment. However, clinical implementation requires careful consideration of tissue penetration, equipment requirements, safety, reproducibility, and treatment practicality.

6. Nanotechnology in Cancer Treatment

Cancer is one of the most intensively investigated applications of nanomedicine. Conventional chemotherapy can produce significant systemic toxicity because many anticancer agents affect both malignant and healthy rapidly dividing cells. Nanocarriers offer the possibility of modifying drug distribution and improving delivery to tumour tissue or tumour cells.

Current cancer nanomedicine includes liposomal drugs, polymeric systems, inorganic nanoparticles, nucleic-acid delivery platforms, and multifunctional nanocarriers. Research is increasingly focused on delivering chemotherapeutics, small interfering RNA, messenger RNA, gene-editing components, immune-modulating agents, and combinations of therapeutic molecules.

Recent research emphasizes hierarchical targeting strategies capable of addressing tumour tissue accumulation, cellular internalization, and subcellular localization. Nevertheless, tumour heterogeneity remains a major obstacle to universal targeting. Current literature indicates that numerous nanomedicines have reached clinical evaluation, but translating highly sophisticated targeted systems into approved therapies remains challenging.

Nanotechnology is also being combined with photothermal and photodynamic approaches. Certain nanoparticles can convert externally supplied energy into heat or facilitate reactive species generation, providing additional mechanisms for destroying cancer cells. Nanomedicine may further be integrated with immunotherapy to stimulate antitumour immune responses.

7. Nanotechnology in Gene and RNA Delivery

Gene and RNA therapies require delivery systems capable of protecting nucleic acids from degradation and transporting them across cellular barriers. Naked nucleic acids can be unstable and may have difficulty reaching their intracellular targets. Nanotechnology provides several strategies for overcoming these limitations.

Lipid nanoparticles have demonstrated particularly important applications in RNA delivery. Their success has encouraged research into delivery of messenger RNA, small interfering RNA, microRNA, and gene-editing components. Nanocarriers may also be designed to control intracellular release and improve the efficiency of therapeutic nucleic acids.

Future applications could include individualized genetic therapies, treatment of inherited diseases, cancer immunotherapy, and transient gene regulation. However, challenges include



immune reactions, tissue-specific delivery, dose optimization, off-target effects, manufacturing consistency, and long-term safety.

8. Nanotechnology in Infectious Diseases

Nanotechnology is increasingly investigated for infectious disease management. Nanoparticles may serve as carriers for antimicrobial agents, vaccine components, or nucleic acids. Their surface properties can also influence interactions with microorganisms.

Nanotechnology may help address certain limitations of conventional antimicrobial therapies by improving drug concentration at infection sites or combining multiple functions in a single platform. Nanomaterials have also been explored as antimicrobial agents themselves.

The development of nanotechnology-based treatments for viral infections has attracted substantial interest, particularly because nanoparticle systems can deliver delicate biological molecules. Research reviews have highlighted applications in both cancer and viral disease treatment.

Nevertheless, antimicrobial nanomaterials must be evaluated carefully because interactions with host cells may produce toxicity. The therapeutic objective is therefore to maximize activity against pathogens while minimizing damage to human tissues.

9. Nanotechnology in Neurological and Cardiovascular Medicine

The central nervous system presents unique barriers to drug delivery, particularly because the blood-brain barrier restricts the movement of many therapeutic molecules from circulation into brain tissue. Nanoparticles are being investigated as potential carriers capable of improving delivery across or around biological barriers.

Potential applications include treatment of neurodegenerative diseases, brain tumours, neurological infections, and other central nervous system disorders. However, successful brain delivery remains highly complex because nanoparticles must overcome multiple biological barriers and must be evaluated for long-term neurological safety.

In cardiovascular medicine, nanotechnology is being investigated for targeted delivery of drugs, imaging agents, and regenerative therapeutics. Potential applications include atherosclerosis, thrombosis, myocardial injury, and vascular inflammation. Targeted systems could theoretically deliver therapeutic agents to diseased vascular regions while reducing systemic exposure.

10. Nanotechnology and Regenerative Medicine

Nanotechnology also has an important role in tissue engineering and regenerative medicine. Nanostructured materials can mimic certain features of the extracellular environment and influence cell attachment, proliferation, differentiation, and tissue organization.

Nanofibrous scaffolds and nanopatterned surfaces can provide physical environments that support tissue regeneration. Nanoparticles can additionally deliver growth factors, genes, or other signalling molecules.



Applications are being explored in bone, cartilage, skin, nerve, and cardiovascular tissue regeneration. The combination of nanotechnology with stem-cell biology and biomaterials may eventually contribute to personalized regenerative medicine.

11. Nanotheranostics

Nanotheranostics combines diagnosis and treatment within an integrated nanoscale platform. A theranostic nanoparticle may contain a therapeutic component together with an imaging or diagnostic component.

This approach could permit clinicians to visualize disease, deliver treatment, monitor response, and potentially adjust therapy. Cancer is a particularly important area because imaging agents can potentially help identify tumour locations while therapeutic components simultaneously act on malignant cells.

Nanoparticles have been investigated as contrast agents, nanoprobes, biosensors, and therapeutic carriers in cancer diagnosis and treatment.

The concept is particularly compatible with precision medicine because treatment decisions could potentially be informed by biological information obtained from the same platform. However, combining multiple functions increases design complexity and creates additional regulatory and manufacturing challenges.

12. Safety and Toxicological Challenges

The promise of nanotechnology must be balanced against potential safety concerns. Nanoparticles may interact with biological systems differently from conventional pharmaceutical compounds because their size, surface properties, shape, and composition influence their behaviour.

Potential concerns include oxidative stress, inflammation, immune responses, organ accumulation, cellular toxicity, and unexpected interactions with proteins and biological membranes. The toxicity of nanoparticles can vary substantially according to material, size, shape, surface charge, dose, route of administration, and duration of exposure.

Metal nanoparticles are an especially important area of investigation. Their unique physicochemical characteristics may provide therapeutic advantages but can also create toxicological challenges. Recent reviews emphasize the need for systematic evaluation of safety alongside therapeutic potential.

Environmental considerations should also be considered. Manufacturing, disposal, and environmental release of nanomaterials may produce ecological effects that require further investigation. Responsible nanomedicine therefore requires assessment across the complete lifecycle of nanomaterials.

13. Manufacturing and Regulatory Challenges

One of the major barriers to clinical translation is the complexity of manufacturing nanomedicines. Small variations in particle size, surface chemistry, composition, aggregation, or drug loading can affect biological performance. Large-scale production must therefore maintain consistent quality.



Manufacturing complexity also affects cost. Sophisticated nanoparticles may require specialized equipment, highly controlled production environments, advanced characterization, and stringent quality-control systems.

Regulatory evaluation can be complicated because nanomedicines may have characteristics that differ substantially from conventional pharmaceutical formulations. Regulatory authorities must assess not only the active pharmaceutical ingredient but also the carrier, manufacturing process, physicochemical properties, stability, pharmacokinetics, biodistribution, toxicity, and clinical performance.

Recent literature identifies manufacturing reproducibility, biological validation, and regulatory alignment as critical components of successful clinical translation.

14. Future Perspectives

The future of nanomedicine is likely to move toward increasingly intelligent, multifunctional, and personalized delivery systems. Researchers are developing nanoparticles capable of responding dynamically to biological conditions and delivering combinations of therapeutic agents.

Artificial intelligence may also contribute to nanoparticle design by helping researchers predict relationships between particle properties and biological outcomes. Machine learning could potentially assist in optimizing formulations, predicting toxicity, identifying suitable targeting ligands, and analyzing large experimental datasets.

Another important direction is biomimetic nanotechnology. Nanoparticles coated with biological membranes or inspired by natural extracellular vesicles may benefit from biological characteristics that influence circulation, immune recognition, or tissue interaction. Such systems remain an active research area and require extensive validation before widespread clinical adoption.

The integration of nanotechnology with genomics, artificial intelligence, immunology, regenerative medicine, and precision medicine could produce highly individualized therapeutic platforms. However, future success will depend on translating laboratory innovations into reproducible, safe, affordable, scalable, and clinically meaningful technologies.

15. Conclusion

Nanotechnology has significantly expanded the possibilities of modern drug delivery and medical treatment. Nanocarriers can improve drug solubility, stability, circulation, cellular uptake, and controlled release, while targeted and stimulus-responsive systems offer opportunities for more selective therapy. Applications extend across cancer, infectious diseases, gene and RNA therapy, neurological disorders, cardiovascular disease, regenerative medicine, vaccines, diagnostics, and theranostics.

The strongest evidence of nanotechnology's medical importance comes from the increasing development and clinical evaluation of nanomedicines, particularly lipid and polymer-based delivery systems. Recent research demonstrates continuing advances in cancer nanomedicine, RNA delivery, targeted therapeutics, and multifunctional diagnostic platforms.



Nevertheless, nanomedicine should not be regarded as a technology without limitations. Biological heterogeneity, nanoparticle toxicity, manufacturing complexity, reproducibility, regulatory requirements, cost, and uncertainty concerning long-term effects remain significant challenges. The future of the field therefore depends on combining innovative nanomaterial design with rigorous pharmacology, toxicology, clinical research, manufacturing science, and ethical governance.

Ultimately, the greatest potential of nanotechnology lies not simply in making medicines smaller, but in making treatment more precise, controllable, biologically compatible, and responsive to individual disease characteristics. Continued interdisciplinary research may enable nanomedicine to become an increasingly important component of precision and personalized healthcare.

References

1. Ashraf, M., Zulfiqar, F., Ijaz, U., Rauf, U., Riaz, M., Arshad, S., Khan, M. J., & Sahin, T. (2025). Nanotechnology, nano-systems and applications of nanoparticles in novel drug delivery: A comprehensive review. *Pakistan Journal of Pharmaceutical Sciences*.
2. Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023). Nanomedicine in cancer therapy. *Signal Transduction and Targeted Therapy*, 8, 293.
3. Fang, R. H., Gao, W., & Zhang, L. (2023). Targeting drugs to tumours using cell membrane-coated nanoparticles. *Nature Reviews Clinical Oncology*, 20, 33–48.
4. Jain, R. K., & Stylianopoulos, T. (2010). Delivering nanomedicine to solid tumors. *Nature Reviews Clinical Oncology*, 7, 653–664.
5. Karahmet Sher, E., Alebić, M., Marković Boras, M., et al. (2024). Nanotechnology in medicine revolutionizing drug delivery for cancer and viral infection treatments. *International Journal of Pharmaceutics*, 660, 124345.
6. Ma, X., et al. (2024). Nanotechnology in healthcare, and its safety and environmental risks. *Journal of Nanobiotechnology*.
7. Mehmood, S., Iraqui, S., Ojha, R. K., Sharma, N., & Marlinda, A. R. (2025). Therapeutic potential and toxicological challenges of metal nanoparticles in drug delivery: A comprehensive review. *Nanomedicine*.
8. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. *Nature Reviews Cancer*, 17, 20–37.
9. Karati, D., Gayen, S., Mukherjee, S., & Roy, S. (2025). An explicative review on nanotechnology-based drug delivery systems for alleviating oxidative stress-driven pathologies. *Current Drug Metabolism*, 26(7), 431–454.
10. Q&A Translational Cancer Nanomedicine. (2025). *Nature Communications*, 16, 8288.
11. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. (2024). *Signal Transduction and Targeted Therapy*.
12. Nanomedicine-based cancer immunotherapy: Recent trends and future perspectives. (2021). *Cancer Gene Therapy*.